Abstract
This paper discusses the status and approach of implementation of good manufacturing practices (GMP) in the Netherlands. Current regulations concerning products for clinical trials are limited and vague. Recent EC Directives on this subject are prompting change in the Netherlands' national regulations, which will make quality of products manufactured for clinical trials the same as quality of all medicinal products.
Get full access to this article
View all access options for this article.